Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

NCT05627414 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Disitamab Vedotin
DRUG: Sintilimab
DRUG: S-1
PROCEDURE: Intraperitoneal chemotherapy with paclitaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital